pyrimidinones and Spinal-Cord-Diseases

pyrimidinones has been researched along with Spinal-Cord-Diseases* in 2 studies

Other Studies

2 other study(ies) available for pyrimidinones and Spinal-Cord-Diseases

Article	Year
Monitoring Arteriovenous Malformation Response to Genotype-Targeted Therapy. Pediatrics, 2020, Volume: 146, Issue:3 Arteriovenous malformations (AVMs) have recently been reported to have a high incidence of somatic KRAS mutations suggesting potential for treatment with mitogen-activated protein kinase inhibitors. In this case report, we describe genotype-targeted treatment of a KRAS mutant metameric AVM in a patient with Cobb syndrome using the mitogen-activated protein kinase inhibitor trametinib. Therapeutic response was monitored with phase-contrast magnetic resonance angiography to quantify AVM arterial inflow as an imaging biomarker. Treatment with trametinib resulted in a substantial decrease in blood flow to the AVM, with a >75% reduction in arterial inflow after 6 months of trametinib therapy. Topics: Adolescent; Amino Acid Sequence; Arteriovenous Malformations; Drug Delivery Systems; Genotype; Humans; Male; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Spinal Cord Diseases; Syndrome; Treatment Outcome	2020
Remission of HIV-associated myelopathy after initiation of lopinavir in a patient with extensive previous exposure to highly active antiretroviral therapy. AIDS (London, England), 2002, Nov-22, Volume: 16, Issue:17 Topics: Adult; Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Spinal Cord Diseases	2002

Article

Year

Monitoring Arteriovenous Malformation Response to Genotype-Targeted Therapy.

Pediatrics, 2020, Volume: 146, Issue:3

Arteriovenous malformations (AVMs) have recently been reported to have a high incidence of somatic KRAS mutations suggesting potential for treatment with mitogen-activated protein kinase inhibitors. In this case report, we describe genotype-targeted treatment of a KRAS mutant metameric AVM in a patient with Cobb syndrome using the mitogen-activated protein kinase inhibitor trametinib. Therapeutic response was monitored with phase-contrast magnetic resonance angiography to quantify AVM arterial inflow as an imaging biomarker. Treatment with trametinib resulted in a substantial decrease in blood flow to the AVM, with a >75% reduction in arterial inflow after 6 months of trametinib therapy.

Topics: Adolescent; Amino Acid Sequence; Arteriovenous Malformations; Drug Delivery Systems; Genotype; Humans; Male; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Spinal Cord Diseases; Syndrome; Treatment Outcome

2020

Remission of HIV-associated myelopathy after initiation of lopinavir in a patient with extensive previous exposure to highly active antiretroviral therapy.

AIDS (London, England), 2002, Nov-22, Volume: 16, Issue:17

Topics: Adult; Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Spinal Cord Diseases

2002